Evidence map›Paper›PMID 37715829›Full record

ArticleCellular and molecular life sciences : CMLS2023

Reciprocal negative feedback regulation of ATF6α and PTEN promotes prostate cancer progression.

Tingting Feng, Ru Zhao, Hanwen Zhang, Feifei Sun, Jing Hu, Meng Wang, Mei Qi, Ling Liu, Lin Gao, Yabo Xiao and 4 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Tingting Feng *The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Ru Zhao *The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Hanwen ZhangThe Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Feifei SunThe Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Jing HuDepartment of Pathology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Meng WangThe Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Mei QiDepartment of Pathology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Ling LiuDepartment of Pathology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Lin GaoThe Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Yabo XiaoSchool of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Junhui ZhenThe Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
Weiwen ChenDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Shandong University, Jinan, Shandong, China.
Lin WangBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, NHC Key Laboratory of Biotechnology Drugs, Key Lab for Rare and Uncommon Diseases of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. linwang@sdfmu.edu.cn.
Bo HanThe Key Laboratory of Experimental Teratology, Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China. boh@sdu.edu.cn.ORCID http://orcid.org/0000-0003-4966-1398
Shandong University · CNQilu Hospital of Shandong University · CNShandong First Medical University · CN

Funding

Academic promotion program of Shandong First Medical University LJ001China Postdoctoral Science Foundation 2022M711900Joint Research Fund of Natural Science of Shandong Province ZR2019LZL014National Natural Science Foundation of China 81772760National Natural Science Foundation of China 81972416National Natural Science Foundation of China 81972436National Natural Science Foundation of China 82072850National Natural Science Foundation of China 82172818Natural Science Foundation of Shandong Province ZR202111150013
6 · The paper itself

Abstract

Phosphatase and tensin homolog (PTEN) loss tightly correlates with prostate cancer (PCa) progression and metastasis. Inactivation of PTEN leads to abnormal activation of PI3K/AKT pathway. However, results from clinical trials with AKT inhibitors in PCa have been largely disappointing. Identification of novel regulators of PTEN in PTEN-dysfunctional PCa is urgently needed. Here we demonstrated that the expression level of PTEN is inversely correlated with the signature score of unfolded protein response (UPR) in PCa. Importantly, PTEN suppresses the activity of ATF6α, via interacting to de-phosphorylate ATF6α and consequently inhibiting its nuclear translocation. Conversely, ATF6α promotes the ubiquitination and degradation of PTEN by inducing CHIP expression. Thus, ATF6α and PTEN forms a negative feedback loop during PCa progression. Combination of ATF6α inhibitor with AKT inhibitor suppresses tumor cell proliferation and xenograft growth. Importantly, this study highlighted ATF6α as a therapeutic vulnerability in PTEN dysfunctional PCa.

Indexed as

Phosphatidylinositol 3-KinasesProstatic NeoplasmsAngiogenesis InhibitorsFeedbackHumansMaleProstateProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseAngiogenesis InhibitorsPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanATF6αProstate cancerPTENUPR

Identifiers

PMID37715829
PMCPMC11073217
OpenAlexW4386799243

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.